A wave of landmark clinical research has dramatically expanded the potential reach of one of medicine's most promising kidney drugs. Three major studies published the week of June 5, 2026 — in the New England Journal of Medicine, JAMA, and The Lancet — have confirmed that finerenone, a mineralocorticoid receptor antagonist previously approved for chronic kidney disease (CKD) in patients with type 2 diabetes, also offers significant protection for patients with non-diabetic kidney disease — a far larger and previously undertreated population.

The findings were presented at the 2026 European Renal Association Congress in Glasgow and published simultaneously in the three journals, representing the most concentrated set of finerenone evidence ever released at one time.

"Finerenone significantly slows kidney function decline, reduces the risk of kidney failure, CKD progression, heart failure, cardiovascular death, and all-cause mortality in both diabetic and non-diabetic CKD," according to the MedicalXpress summary of the pooled trial data. "Benefits were consistent across diverse patient groups, with manageable safety concerns."

What the Studies Found

The FIND-CKD Phase 3 trial, published June 5 in the New England Journal of Medicine, tested finerenone in non-diabetic patients with CKD. The drug reduced the risk of kidney failure, CKD progression, heart failure, or cardiovascular death by 23 percent, according to ScienceDaily's review of the findings.

A second study, published in JAMA, extended the findings to patients with CKD caused by glomerular diseases — a category of kidney disorders that affects the filtering units of the kidneys and has historically had few effective treatment options. A third pooled analysis published in The Lancet combined individual participant data from across trials and confirmed consistent benefits across a wide range of CKD patient profiles.

For Houston — a city with one of the highest chronic kidney disease burdens in Texas, driven by its large diabetic and hypertensive population — MedicalDaily.com's analysis noted that this research "is personal." Houston's high rates of diabetes, hypertension, and obesity create one of the largest urban CKD populations in the American South.

Nationwide, an estimated 37 million Americans live with chronic kidney disease. Most cases are caused by diabetes and high blood pressure, but a significant portion — the patients newly shown to benefit from finerenone — have kidney disease from non-diabetic causes, including glomerular disease, autoimmune conditions, and other factors.

What This Means for Patients and Physicians

These studies suggest that finerenone's benefits extend far beyond its current FDA-approved indication for CKD associated with type 2 diabetes. If regulatory agencies in the United States expand the drug's approved indications in response to this evidence, millions of additional patients could become eligible for treatment.

Finerenone works by blocking a receptor in the kidneys and heart that, when overactivated, drives inflammation, fibrosis (scarring), and fluid retention — processes that accelerate kidney function loss and cardiovascular damage. Unlike older drugs in its class, finerenone is highly selective, which means it produces fewer side effects, including the dangerous electrolyte imbalance called hyperkalemia.

Patients with CKD should discuss these new findings with their nephrologist or primary care physician. The drug is not yet approved for non-diabetic CKD, and treatment decisions should be made in consultation with a healthcare provider.

Read more

Frequently Asked Questions

Q: What is finerenone?

A: Finerenone is a prescription drug that blocks a receptor in the kidneys and heart that drives inflammation and scarring. It is currently FDA-approved for CKD associated with type 2 diabetes.

Q: What did the new studies find?

A: Three major studies found that finerenone also significantly slows kidney disease and reduces cardiovascular death in patients without diabetes, including those with glomerular disease — expanding its potential benefit to millions more patients.

Q: Can patients without diabetes now be prescribed finerenone?

A: Not under current FDA-approved indications. Regulatory expansion would require a new approval application. Patients should discuss eligibility with their physician.

Q: How common is chronic kidney disease?

A: Approximately 37 million Americans live with CKD. It is often caused by diabetes and high blood pressure, and it frequently goes undiagnosed until advanced.

Q: What cities are most affected by CKD?

A: Cities with high rates of diabetes and obesity, including Houston, Los Angeles, Chicago, and Detroit, carry particularly high CKD burdens.